Should I Buy TEVA? TEVA 2026 Analysis

Should You Buy Teva Pharmaceutical Industries Ltd (TEVA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

30.470

1 Day change

-3.33%

52 Week Range

37.340

Analysis Updated At

2026/03/06

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Teva Pharmaceuticals does not present a strong buying opportunity at this moment for a beginner, long-term investor with $50,000-$100,000 to invest. Despite positive analyst sentiment and strategic developments, the technical indicators, recent financial performance, and cautious trading sentiment suggest it is better to wait for a more favorable entry point.

Technical Analysis

The stock is currently in a downtrend, with the MACD histogram at -0.415 and negatively expanding, indicating bearish momentum. RSI is at 19.198, signaling oversold conditions, but the price is still below the pivot level of 32.92, with support at 31.327 and resistance at 34.513. Converging moving averages suggest indecision in the market.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Teva has entered a $400 million strategic funding agreement with Blackstone Life Sciences to support the clinical development of duvakitug, a promising drug for ulcerative colitis and Crohn's disease. Analysts have raised price targets and remain bullish on the stock, citing an attractive long-term growth story, improved capital structure, and innovative R&D efforts.

Neutral/Negative Catalysts

is also down by -0.94%.

Financial Performance

In Q4 2025, Teva reported a 12.61% YoY increase in revenue to $4.725 billion. However, net income dropped significantly by -321.20% YoY to $480 million, and EPS fell by -315.79% YoY to 0.41. Gross margin improved to 56.74%, up 10.54% YoY, indicating some operational efficiency gains.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are overwhelmingly positive on Teva, with multiple firms raising price targets (ranging from $36 to $45) and maintaining Buy or Overweight ratings. They cite strong execution, innovative R&D, and a de-risked growth path as key drivers for optimism. However, some analysts note that valuation is becoming a concern as the stock trades above historical multiples.

11 Analyst Rating

Wall Street analysts forecast TEVA stock price to rise

10 Buy

1 Hold

0 Sell

Strong Buy

Current: 31.520

Low

Averages

35.71

High

Current: 31.520

Low

Averages

35.71

High

Piper Sandler

David Amsellem

Overweight

maintain

$40 -> $41

AI Analysis

2026-03-04

Reason

Piper Sandler

David Amsellem

Price Target

$40 -> $41

AI Analysis

2026-03-04

maintain

Overweight

Reason

Piper Sandler analyst David Amsellem raised the firm's price target on Teva to $41 from $40 and keeps an Overweight rating on the shares after meeting with management. Key discussion topics included a number of bigger picture considerations, including management's approach to innovative R&D and its vision for the R&D organization; how the team is thinking about further build-out of its core neuroscience and immunology verticals; its vision for the biosimilars business; and the approach to capital deployment amid growth in cash generation. With an attractive long-term top-line/EBITDA growth story coming into focus, in the context of continued improvement in the capital structure and an absence of loss of exclusivity exposure, the firm would argue for further multiple expansion from a current EV/2026 EBITDA of 10 times.

BofA

Buy

maintain

$37 -> $38

2026-02-18

Reason

BofA

Price Target

$37 -> $38

2026-02-18

maintain

Buy

Reason

BofA raised the firm's price target on Teva (TEVA) to $38 from $37 and keeps a Buy rating on the shares after the company and partner Sanofi (SNY) announced Phase 2 maintenance data from the RELIEVE UCCD long-term extension study of duvakitug in inflammatory bowel diseases. Based on yesterday's update, the firm edged up its multiple, reflecting $1B in higher duvakitug peak sales, now seen at a $3B peak.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TEVA

Unlock Now

TEVA Should I Buy

TEVA Should I Buy

Should You Buy Teva Pharmaceutical Industries Ltd (TEVA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch